Zevra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Zevra Therapeutics

28/03/2024 22:51

* Zevra Therapeutics Inc  ZVRA.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -26 cents.  The mean expectation of six analysts for the
quarter was for a loss of 27 cents per share. Wall Street
expected results to range from -54 cents to -4 cents per share.
    * Revenue rose 469.9% to $13.22 million from a year ago;
analysts
expected $11.74 million. 
    * Zevra Therapeutics Inc's reported EPS for the quarter was
a loss
of 40 cents​.
    * The company reported a quarterly loss of $15.15 million.
    * Zevra Therapeutics Inc shares had fallen by 9.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Zevra
Therapeutics Inc is $18.50 
This summary was machine generated from LSEG data March 28 at
10:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.27          -0.40          Missed
 Sep. 30 2023      -0.30          -0.40          Missed
 Jun. 30 2023      -0.34          -0.15          Beat
 Mar. 31 2023      -0.23          -0.34          Missed